Chardan Capital Maintains Buy on Passage Bio, Lowers Price Target to $9
Chardan Capital Maintains Buy on Passage Bio, Lowers Price Target to $9
Chardan Capital維持對Passage Bio的買入,將目標股價下調至9美元
Chardan Capital analyst Geulah Livshits maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $11 to $9.
Chardan Capital分析師Geulah Livshits維持Passage Bio(納斯達克股票代碼:PASG)的買入,並將目標股價從11美元下調至9美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。